Skip to main content

Corlanor Side Effects

Generic name: ivabradine

Medically reviewed by Drugs.com. Last updated on Apr 3, 2023.

Note: This document contains side effect information about ivabradine. Some dosage forms listed on this page may not apply to the brand name Corlanor.

Applies to ivabradine: oral solution, oral tablet.

Serious side effects of Corlanor

Along with its needed effects, ivabradine (the active ingredient contained in Corlanor) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking ivabradine:

More common

Incidence not known

Other side effects of Corlanor

Some side effects of ivabradine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to ivabradine: oral liquid, oral tablet.

General

The most common side effects were cardiac failure, phosphene-like events, and bradycardia.[Ref]

Cardiovascular

Very common (10% or more): Cardiac failure (21.7%), bradycardia (up to 10%)

Common (1% to 10%): Hypertension, blood pressure increased, atrial fibrillation, ventricular extrasystoles, atrioventricular block first degree, unstable angina, angina pectoris aggravated, myocardial ischemia, blood pressure inadequately controlled, sinus tachycardia, supraventricular extrasystoles, atrial flutter, ventricular tachycardia, bradycardia symptomatic, bradycardia asymptomatic, angina pectoris, acute myocardial infarction, myocardial infarction, hypotension, sudden cardiac death

Uncommon (0.1% to 1%): Palpitations, sinus arrhythmia, ECG prolonged QT interval

Very rare (less than 0.01%): Atrioventricular block second degree, atrioventricular block third degree, sick sinus syndrome

Postmarketing reports: Torsade de pointes, ventricular fibrillation[Ref]

Ocular

Very common (10% or more): Phosphene-like events (14.5%)

Common (1% to 10%): Phosphenes, visual brightness, blurred vision

Uncommon (0.1% to 1%): Diplopia, visual impairment[Ref]

Phosphenes generally occur within the first 2 months of treatment and may occur repeatedly afterward. They were generally reported as mild to moderate in intensity and led to discontinuation in less than 1% of patients. Most cases resolved during or after treatment.[Ref]

Respiratory

Common (1% to 10%): Pneumonia, bronchitis acute, bronchitis, nasopharyngitis, upper respiratory tract infection, respiratory tract infection, influenza, cough, chronic obstructive pulmonary disease

Uncommon (0.1% to 1%): Dyspnea[Ref]

Metabolic

Common (1% to 10%): Diabetes mellitus inadequately controlled, diabetes mellitus, hypercholesterolemia, hypokalemia, hyperuricemia[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness, ischemic stroke

Uncommon (0.1% to 1%): Syncope[Ref]

Other

Common (1% to 10%): Sudden death, fall

Uncommon (0.1% to 1%): Vertigo, asthenia, fatigue

Rare (less than 0.1%): Malaise[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea, gastritis

Uncommon (0.1% to 1%): Nausea, constipation, abdominal pain[Ref]

Hematologic

Common (1% to 10%): Blood creatinine increased, anemia

Uncommon (0.1% to 1%): Eosinophilia[Ref]

Renal

Common (1% to 10%): Renal failure[Ref]

Hepatic

Common (1% to 10%): Transaminases increased[Ref]

Dermatologic

Uncommon (0.1% to 1%): Angioedema, rash

Rare (less than 0.1%): Erythema, pruritus, urticaria[Ref]

Musculoskeletal

Uncommon (0.1% to 1%): Muscle cramps[Ref]

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Corlanor (ivabradine). Amgen USA. 2015.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.